Summary
Bristol-Myers Squibb's (BMY) 2018 10-K filing highlights a year of strategic focus on its core therapeutic areas, particularly in oncology, immunology, and cardiovascular diseases. The company's performance in 2018 was shaped by its product portfolio, ongoing research and development efforts, and strategic partnerships. Investors should note the company's commitment to innovation, as evidenced by its significant R&D investments, aimed at building a robust pipeline of new therapies. The filing underscores BMY's market position and competitive landscape, detailing its approach to pricing, market access, and government regulation, all of which are critical factors in the pharmaceutical industry. The company emphasizes its robust manufacturing capabilities and quality assurance processes, ensuring the reliable supply of its medicines. While the report focuses on operational and financial performance, it also acknowledges the inherent risks and uncertainties faced by the company, including those related to drug development, regulatory approvals, and market competition.
Financial Highlights
58 data points| Revenue | $22.56B |
| Cost of Revenue | $6.47B |
| Gross Profit | $16.09B |
| R&D Expenses | $6.33B |
| SG&A Expenses | $4.55B |
| Operating Expenses | $16.59B |
| Interest Expense | $183.00M |
| Net Income | $4.92B |
| EPS (Basic) | $3.01 |
| EPS (Diluted) | $3.01 |
| Shares Outstanding (Basic) | 1.63B |
| Shares Outstanding (Diluted) | 1.64B |
Key Highlights
- 1Strong focus on core therapeutic areas: Oncology, Immunology, and Cardiovascular diseases.
- 2Significant investment in Research and Development (R&D) to fuel pipeline growth and innovation.
- 3Emphasis on strategic alliances and partnerships to advance drug development and market reach.
- 4Detailed discussion of competitive landscape, pricing strategies, and market access challenges.
- 5Commitment to manufacturing excellence and quality assurance for product supply.
- 6Acknowledgement of regulatory environment and its impact on business operations.
- 7Inclusion of risk factors pertinent to the pharmaceutical industry, including clinical trial success and patent exclusivity.